[ad_1]
The University of Oxford / AstraZeneca’s first COVID-19 vaccination will apparently happen next Monday.
Sarah Tew / CNET
For the most up-to-date news and information on the coronavirus pandemic, visit the WHO website.
The University of Oxford and AstraZeneca Vaccine for COVID-19 it was approved for emergency supply in the UK, the UK government said on Wednesday. This follows the Modern and Pfizer vaccines that got approval last month.
Like the other two, the Oxford vaccine will require two doses. In this case, the second injection should be given between four and 12 weeks after the first.
The first person will receive the Oxford vaccine on January 4, UK Health Secretary Matt Hancock told the BBC, and the UK ordered enough to vaccinate the country’s entire adult population.
“This is a time to celebrate British innovation – not only are we responsible for discovering the first treatment to reduce mortality from COVID-19, this vaccine will be available to some of the world’s poorest regions at a low cost, helping to protect countless people from this terrible disease, “Hancock said in a statement.
Read more: COVID-19 Vaccine Facts: Hidden Costs, When Can You Get Vaccinated
Unlike the Pfizer vaccine, which must be kept at ultra-cold temperatures, the Oxford vaccine can be stored under “normal refrigeration conditions,” AstraZeneca said. (The Moderna vaccine can also be refrigerated.)
The approval comes after a new “highly contagious” strain of coronavirus was detected in the UK last month, sending the country into a strict lockdown during the Christmas season. This first American case of this new variant was discovered on Tuesday, in Colorado.
The European Medicines Agency (EMA) will not evaluate the Oxford vaccine until January at the earliest because it has not received an application from AstraZeneca, while US regulators are waiting for a late-stage trial to complete, according to the Financial. Times.
“The EMA is currently evaluating the data on this vaccine as part of an ongoing review, which began on October 1, 2020,” an EMA spokesperson said in an emailed statement to CNET. “The EMA’s Committee for Human Medicines (CHMP) has evaluated data from laboratory studies (non-clinical data) and is currently evaluating data on the quality of the vaccine (on its ingredients and the way it is manufactured), as well as evidence on its efficacy and safety from several ongoing clinical trials. “
The US Food and Drug Administration declined to comment on the Oxford vaccine specifically, but a spokesperson noted by email that it is “committed to providing the same fast, thorough and transparent review process” that it applied to vaccines. Pfizer and Moderna for any future emergency use. Authorization requests.
The information in this article is for educational and informational purposes only and is not intended to be medical or health advice. Always consult a physician or other qualified healthcare provider regarding any questions you may have about a medical condition or health goals.
